Biotech News

Chemomab to Participate in Oppenheimer’s Movers in Rare Disease Summit

Chemomab Therapeutics (CMMB)Chemomab TherapeuticsCompany update

CMMB (CMMB) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is cmmb.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Related news

Chemomab Therapeutics

Immune-Fibrotic Disease Company Chemomab Therapeutics is a clinical-stage biotechnology company developing therapies for diseases driven by fibrosis and inflammation. Its research is centered on CCL24, a soluble signaling protein implicated in immune-cell recruitment, tissue remodeling, and fibrotic disease progression. CCL24...

Recent company news

Stock data

Close
2.16 USD
Market cap
12.53M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States